

# VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS OPTIONS FOR SURGERY

Surgery Type	Recommended Prophylaxis Options <sup>1</sup>
<b>Intracranial Neurosurgery</b> Appendix A, Table 5.17 <sup>+</sup>	<p>Any of the following:</p> <ul style="list-style-type: none"> <li>▶ Intermittent pneumatic compression devices (IPC) with or without graduated compression stockings (GCS)</li> <li>▶ Low-dose unfractionated heparin (LDUH)</li> <li>▶ Low molecular weight heparin (LMWH)<sup>2</sup></li> <li>▶ LDUH or LMWH<sup>2</sup> combined with IPC or GCS</li> </ul> <p><sup>2</sup> Current guidelines recommend postoperative low molecular weight heparin for intracranial neurosurgery.</p>
<b>General Surgery</b> Appendix A, Table 5.19 <sup>+</sup>	<p>Any of the following:</p> <ul style="list-style-type: none"> <li>▶ Low-dose unfractionated heparin (LDUH)</li> <li>▶ Low molecular weight heparin (LMWH)</li> <li>▶ Factor Xa Inhibitor (fondaparinux)</li> <li>▶ LDUH or LMWH or Factor Xa Inhibitor (fondaparinux) combined with IPC or GCS</li> </ul> <p>With a documented reason for not using pharmacological prophylaxis use any of the following:</p> <ul style="list-style-type: none"> <li>▶ Graduated compression stockings (GCS)</li> <li>▶ Intermittent pneumatic compression devices (IPC)</li> </ul>
<b>Gynecologic Surgery</b> Appendix A, Table 5.20 <sup>+</sup>	<p>Any of the following:</p> <ul style="list-style-type: none"> <li>▶ Low-dose unfractionated heparin (LDUH)</li> <li>▶ Low molecular weight heparin (LMWH)</li> <li>▶ Factor Xa Inhibitor (fondaparinux)</li> <li>▶ Intermittent pneumatic compression devices (IPC)</li> <li>▶ LDUH or LMWH or Factor Xa Inhibitor (fondaparinux) combined with IPC or GCS</li> </ul>
<b>Urologic Surgery</b> Appendix A, Table 5.21 <sup>+</sup>	<p>Any of the following:</p> <ul style="list-style-type: none"> <li>▶ Low-dose unfractionated heparin (LDUH)</li> <li>▶ Low molecular weight heparin (LMWH)</li> <li>▶ Factor Xa Inhibitor (fondaparinux)</li> <li>▶ Intermittent pneumatic compression devices (IPC)</li> <li>▶ Graduated compression stockings (GCS)</li> <li>▶ LDUH or LMWH or Factor Xa Inhibitor (fondaparinux) combined with IPC or GCS</li> </ul>
<b>Elective Total Hip Replacement</b> Appendix A, Table 5.22 <sup>+</sup>	<p>Any of the following started within 24 hrs of surgery:</p> <ul style="list-style-type: none"> <li>▶ Low molecular weight heparin (LMWH)</li> <li>▶ Factor Xa Inhibitor (fondaparinux)</li> <li>▶ Oral Factor Xa Inhibitor<sup>3</sup></li> <li>▶ Warfarin</li> </ul> <p>With a documented reason for not using pharmacological prophylaxis use any of the following:</p> <ul style="list-style-type: none"> <li>▶ Intermittent pneumatic compression devices (IPC)</li> <li>▶ Venous foot pump (VFP)</li> </ul>
<b>Elective Total Knee Replacement</b> Appendix A, Table 5.23 <sup>+</sup>	<p>Any of the following:</p> <ul style="list-style-type: none"> <li>▶ Low molecular weight heparin (LMWH)</li> <li>▶ Factor Xa Inhibitor (fondaparinux)</li> <li>▶ Oral Factor Xa Inhibitor<sup>3</sup></li> <li>▶ Warfarin</li> <li>▶ Intermittent pneumatic compression devices (IPC)</li> <li>▶ Venous foot pump (VFP)</li> </ul>
<b>Hip Fracture Surgery</b> Appendix A, Table 5.24 <sup>+</sup>	<p>Any of the following:</p> <ul style="list-style-type: none"> <li>▶ Low-dose unfractionated heparin (LDUH)</li> <li>▶ Low molecular weight heparin (LMWH)</li> <li>▶ Factor Xa Inhibitor (fondaparinux)</li> <li>▶ Warfarin</li> </ul> <p>With a documented reason for not using pharmacological prophylaxis use any of the following:</p> <ul style="list-style-type: none"> <li>▶ Graduated compression stockings (GCS)</li> <li>▶ Intermittent pneumatic compression devices (IPC)</li> <li>▶ Venous foot pump (VFP)</li> </ul>

<sup>1</sup>Patients who receive neuraxial anesthesia or have a documented contraindication to pharmacological prophylaxis may pass the performance measure if either appropriate pharmacological or mechanical prophylaxis is ordered.

Geerts WH, Bergquist, D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism. The Eight ACCP Conference on antithrombotic and thrombolytic therapy. Chest 2008; 133:381S-453S. PMID: 18574271.

<sup>+</sup>Adapted from Specifications Manual for National Hospital Inpatient Quality Measures Discharges 01-01-12 (1Q12) through 06-30-12 (2Q12)

<sup>3</sup> The U.S. Food & Drug Administration has approved Xarelto (rivaroxaban) to reduce the risk of blood clots, deep vein thrombosis (DVT) & pulmonary embolism (PE) following knee or hip replacement surgery ONLY.

